Parexel is a finalist for the SCRS 2026 Eagle Award.
Public source
Publisher name
Public post
Parexel is a finalist for the SCRS 2026 Eagle Award! 🦅 This meaningful recognition is especially significant because it is voted on exclusively by research site profess…
Company
Parexel
- Industry
- Pharmaceutical Manufacturing
- Location
- Raleigh, US
- Company size
- 10,001+ employees
About Parexel
Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 22,000+ global employees work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove any comments that do not adhere to our guidelines as well as report users who violate the rules of our page.
See moreLatest activity
Latest activity from Parexel
56 signals
Research & Knowledge
Parexel published an analysis in the New Medicines, Novel Insights newsletter examining the changes introduced by the FDA's proposed PDUFA VIII commitment letter, including earlier FDA engagement, greater focus on CMC readiness, and expanded meeting opportunities.
Presence & Recognition
Parexel participated in a discussion at Nordic Life Science Days on Breakthrough Developments in CNS.
Presence & Recognition
Parexel team is attending DPHARM 2026 in Boston at booth #531 to explore clinical development innovations and AI.
Discover more
Similar signals
Similar public activity from other companies.
Presence & Recognition
Medpace
Medpace has been named a finalist for the 2026 Society for Clinical Research Sites (SCRS) Eagle Award
Presence & Recognition
Society for Clinical Research Sites (SCRS)
Society for Clinical Research Sites (SCRS) announced that the 2026 Eagle Award CRO finalists include IQVIA, Medpace, Novotech, Parexel, and Worldwide Clinical Trials.
Presence & Recognition
Innovative Trials
Innovative Trials Academy will be sharing exactly how you can get involved post-SCRS at the Society for Clinical Research Sites Global Summit next month.
Presence & Recognition
PSI CRO
PSI CRO will meet with sponsors at ESMO 2026 to discuss oncology enrollment strategy, data quality, and execution across pivotal programs.
Presence & Recognition
Precision Medicine Group